In 1911, Alois Alzheimer published a detailed report (Zbl. ges. Neurol. Psych. 4: 356-385) on a peculiar case of the disease that had been named after him by Emil Kraepelin in 1910. Alzheimer describes a 56-year-old male patient (Johann F.) who suffered from presenile dementia and who was hospitalized in Kraepelin's clinic for more than 3 years. Post-mortem examination of the patient's brain revealed numerous amyloid plaques but no neurofibrillary tangles in the cerebral cortex, corresponding to a less common form of Alzheimer disease which may be referred to as 'plaque only'. We have identified well-preserved histological sections of this case and performed mutational screening of exon 17 of the amyloid precursor protein gene and genotyping for apolipoprotein E alleles. The patient was shown to be homozygous for apolipoprotein allele epsilon3 and lacked APP mutations at codons 692, 693, 713 and 717. This case is of historical importance as it may have convinced Kraepelin to name the disease after his co-worker, Alois Alzheimer.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s100480050011DOI Listing

Publication Analysis

Top Keywords

alois alzheimer
12
alzheimer
5
rediscovery case
4
case described
4
described alois
4
alzheimer 1911
4
1911 historical
4
historical histological
4
histological molecular
4
molecular genetic
4

Similar Publications

Alois Alzheimer was a German psychologist and neuropathologist who significantly advanced the study of dementia with his discovery of Alzheimer's disease (AD). Based on his assessment of a 51-year-old female patient with symptoms of presenile dementia and after conducting a postmortem autopsy of her brain, Alzheimer distinguished two neurological substances - senile plaques and neurofibrillary tangles - as unique markers of what was later deemed as AD. He recognized that dementia is not a natural consequence of age but rather a recognizable neurocognitive disorder.

View Article and Find Full Text PDF
Article Synopsis
  • German neurologist Alois Alzheimer first described Alzheimer's disease (AD) over a century ago, linking cognitive impairments to abnormal protein clusters like amyloid plaques and tau tangles in the brain.
  • Aging disrupts the balance of amyloid-β (Aβ) levels, leading to its accumulation, which is associated with neurodegeneration; despite skepticism about targeting Aβ for treatment, recent FDA approvals of anti-Aβ drugs have sparked new interest in this approach.
  • Our research has identified a small molecule, EPPS, which effectively reduces aggregated Aβ in the brain and improves behavior in AD models by breaking down toxic aggregates into harmless monomers, potentially offering a more accessible treatment option compared to antibody therapies.
View Article and Find Full Text PDF

Over a century has passed since Alois Alzheimer first described Alzheimer's disease (AD), and since then, researchers have made significant strides in understanding its pathology. One key feature of AD is the presence of amyloid-β (Aβ) peptides, which form amyloid plaques, and therefore, it is a primary target for treatment studies. Naturally occurring peptides have garnered attention for their potential pharmacological benefits, particularly in the central nervous system.

View Article and Find Full Text PDF

Alzheimer's disease and its treatment-yesterday, today, and tomorrow.

Front Pharmacol

May 2024

Department of Pharmacology and Medical Education, Weill Cornell Medicine-Qatar, Doha, Qatar.

Article Synopsis
  • Alois Alzheimer identified the first Alzheimer's disease (AD) patient in 1907, and today AD is the leading form of dementia, affecting over 47 million people worldwide, with projections showing numbers could exceed 130 million by 2050.
  • In the U.S., approximately six million individuals currently have AD, with expectations of this number doubling by 2050, alongside nearly 12 million experiencing mild cognitive impairment (MCI), which is a precursor to AD.
  • The review discusses the limitations of current drugs for AD, emphasizing that while amyloid-β (Aβ) and tau proteins are potential drug targets, existing anti-Aβ therapies may not be the ultimate solution, suggesting a need for research into alternative treatment strategies
View Article and Find Full Text PDF

Since its first description in 1906 by Dr. Alois Alzheimer, Alzheimer's disease (AD) has been the most common type of dementia. Initially thought to be caused by age-associated accumulation of plaques, in recent years, research has increasingly associated AD with lysosomal storage and metabolic disorders, and the explanation of its pathogenesis has shifted from amyloid and tau accumulation to oxidative stress and impaired lipid and glucose metabolism aggravated by hypoxic conditions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!